Alnylam enjoyed a very successful year in 2019, gaining US approval for its second RNA interference (RNAi) therapy, Givlaari (givosiran), with two more of its drug progressing towards regulatory filing.
The firm was the originator of inclisiran, developed by The Medicines Company, which has just been acquired by Novartis, and the Swiss major hopes to turn the cholesterol-lowering RNAi drug into a blockbuster. Meanwhile, lumisiran, Alnylam’s next in-house molecule, produced pivotal data in primary hyperoxaluria type 1 (PH1), and both drugs are on track for early 2020 filing and approval later this year
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?